Etoposide phosphate disodium

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

122405-33-8

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

BMY-40481 disodium

产品介绍

Etoposide phosphate disodium (BMY-40481 disodium) 是一种有效的抗癌 (anti-cancer) 化疗试剂和一种选择性拓扑异构酶 II (topoisomerase II) 抑制剂，可以防止 DNA 链的重新连接。Etoposide phosphate disodium 是依托泊苷的磷酸酯前药，被认为与 Etoposide 活性相当。Etoposide phosphate disodium 诱导细胞周期阻滞、凋亡 (apoptosis) 和自噬 (autophagy)。

生物活性

Etoposide phosphate disodium (BMY-40481 disodium) is a potentanti-cancerchemotherapy agent and a selectivetopoisomeraseIIinhibitor to prevent re-ligation of DNA strands. Etoposide phosphate disodium is the phosphate ester prodrug of etoposide and is considered as active equivalent to Etoposide. Etoposide phosphate disodium induces cell cycle arrest, apoptosis, and autophagy^[1]^[2].

IC₅₀& Target^[2]

Topoisomerase II

体外研究
(In Vitro)

Etoposide phosphate disodium is a water-soluble derivative and probable prodrug of etoposide characterized by the presence of a phosphate group in position 4' of the E ring of the etoposide molecule^[1].
Etoposide phosphate disodium (0-1 μM; 72 hours) inhibits HCT116 FBXW^+/+, FBXW^-/-and p53^-/-as a dose-dependent manner, exhibits IC₅₀values of 0.945 μM; 0.375 μM; and 1.437 μM, respectively^[2].
Etoposide phosphate disodium (25 μM; 6 hours) delays p53 recover in FBXW7-deficient cells. In addition, FBXW7 expression is disappeared in FBXW7^-/-cells^[2].

Cell Viability Assay^[2]

Cell Line:	FBXW^+/+, FBXW^-/-and p53^-/-cell
Concentration:	0.025 μM, 0.05 μM, 0.075 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.6 μM, 0.8 μM, 1 μM
Incubation Time:	72 hours
Result:	Inhibited HCT116 FBXW^+/+, FBXW^-/-and p53^-/-cell growth as a concentration manner.

Western Blot Analysis^[2]

Cell Line:	HCT116 FBXW7^+/+or FBXW7^-/-cells
Concentration:	25 μM
Incubation Time:	6 hours
Result:	Exhibited that the recovery of p53 levels after DNA damage is mediated by FBXW7.

体内研究
(In Vivo)

Etoposide phosphate (intravenous injection; 50, 100, or 150 mg/kg; single dose) has clinical symptomology of progressive ataxia, impaired righting reflex, and splaying and paresis of fore- and hindlimbs at day 8 in female CD-1 mice^[3].

Animal Model:	Female CD-1 mice^[3]
Dosage:	50, 100, or 150 mg/kg
Administration:	Intravenous injection; single dose
Result:	Observed degeneration of dorsal root ganglion cells and axonal degeneration of their distal and proximal processes in peripheral nerves, dorsal spinal roots, and dorsal funiculi of the spinal cord at all doses under light microscopy (LM).

Clinical Trial

分子量

712.50

Formula

C₂₉H₃₁Na₂O₁₆P

CAS 号

122405-33-8

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.